Company: STAA
Filing Date: 2025-12-19
Form Type: DFAN14A
Source: 0001213900-25-123935
Chunk: 7

Company: STAAR SURGICAL CO
Filing Date: 2025-12-19
Form: DFAN14A
Chunk 7
---
 Price of STAAR Surgical December 8, 2025 Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go - Shop Process December 8, 2025 Broadwood Partners: Proxy Advisory Firm Egan - Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon November 10, 2025 Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go - Shop Process November 4, 2025 Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects SIGN UP FOR UPDATES SUBSCRIBE First Name Last Name Email © 2025 Let STAAR Shine. All rights reserved. Terms of Use. Privacy Policy. Disclaimer. MEDIA August Strategic Communications Scott Deveau / Jeremy Jacobs (323) 805 - 8919 Broadwood@augustco.com INVESTOR CONTACT Saratoga Proxy Consulting, LLC John Ferguson / Joseph Mills (888) 368 - 0379 or (212) 257 - 1311 jferguson@saratogaproxy.com jmills@saratogaproxy.com HOME REASONS TO VOTE AGAINST RESOURCES PRESS/MEDIA HOW TO VOTE CONTACT

5</div>

Exhibit 3

<div align='center'>Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical’s Proposed Sale to Alcon Inc.

Expresses Disappointment in the Board’s and Management’s Continued Pursuit of Ill-advised Deal</div>

CHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ --
Defender Capital (“Defender” or “we”), a long-term shareholder of STAAR Surgical Company (“STAAR”
or the Company”) (NASDAQ: STAA) owning approximately 1.5% of the Company’s outstanding common stock, today issued the following
statement reiterating its intention to vote AGAINST the Company’s proposed sale to Alcon Inc. (“Alcon”) (NYSE: ALC)
and expressing its disappointment in the Company’s Board of Directors’ (the “Board”) continued pursuit of the
deal:

As shareholders of STAAR Surgical for
the past decade, we remain convicted in the long-term potential of the Company and are disappointed that the Board has continued to pursue
the ill-advised sale to Alcon, which we do not believe is in the best interests of STAAR shareholders and does not represent